These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2783201)

  • 1. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
    Lussier-Cacan S; Bard JM; Boulet L; Nestruck AC; Grothé AM; Fruchart JC; Davignon J
    Atherosclerosis; 1989 Aug; 78(2-3):167-82. PubMed ID: 2783201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Deshaies Y; Gagné C; Couture P
    Atherosclerosis; 2006 Sep; 188(1):203-12. PubMed ID: 16337207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fenofibrate treatment on type III hyperlipoproteinemia.
    Fruchart JC; Davignon J; Bard JM; Grothe AM; Richard A; Fievet C
    Am J Med; 1987 Nov; 83(5B):71-4. PubMed ID: 3688011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate affects the compositions of lipoproteins.
    Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
    Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia.
    Dallongeville J; Boulet L; Davignon J; Lussier-Cacan S
    Arterioscler Thromb; 1991; 11(4):864-71. PubMed ID: 2065040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
    Ishigami M; Yamashita S; Sakai N; Hirano K; Hiraoka H; Nakamura T; Matsuzawa Y
    Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
    Weisweiler P; Merk W; Jacob B; Schwandt P
    Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL; East C; Grundy SM
    Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
    Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM
    Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect.
    Davignon J; Dallongeville J; Roederer G; Roy M; Fruchart JC; Kessling AM; Bouthillier D; Lussier-Cacan S
    Ann Med; 1991 Apr; 23(2):161-7. PubMed ID: 1648930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.
    Mellies MJ; Stein EA; Khoury P; Lamkin G; Glueck CJ
    Atherosclerosis; 1987 Jan; 63(1):57-64. PubMed ID: 3548734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
    Ehnholm C; Mahley RW; Chappell DA; Weisgraber KH; Ludwig E; Witztum JL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5566-70. PubMed ID: 6591204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein compositional changes with combination hormone therapy (conjugated estrogen and medroxyprogesterone) in African American women.
    Hughes TA; Pace DT; Ke RW; Tolley EA; Qureshi N; Stentz F
    Endocr Pract; 2004; 10(3):179-86. PubMed ID: 15310534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype.
    Todo Y; Kobayashi J; Higashikata T; Kawashiri M; Nohara A; Inazu A; Koizumi J; Mabuchi H
    Clin Chim Acta; 2004 Oct; 348(1-2):35-40. PubMed ID: 15369733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.